Related Experiment Videos
Thiazolidinediones: from antioxidant to neurotherapeutic?
Roger S McIntyre1, Joanna K Soczynska, Hanna Woldeyohannes
1Department of Psychiatry, University of Toronto, Toronto, Ont., Canada. roger.mcintyre@uhn.on.ca
Abstract:
A prevailing paradigm regarding the pathophysiology of mood disorders posits that these syndromes are possibly neurodegenerative. Alterations in interacting biological networks which subserve metabolism, inflammation, immune function, and stress response are hypothesized to mediate the neurotoxicity and allostasis associated with mood disorders. Preclinical evidence indicates that thiazolidinediones (TZDs) exert neurotherapeutic (e.g., neurotrophic) effects. Preliminary clinical evidence also suggests that TZDs may be salutary for mental disorders in which neurocognitive deficits are a central feature. We propose that TZDs constitute a potentially novel disease-modifying treatment avenue for mood disorders.
Related Concept Videos
Oral Hypoglycemic Agents: Biguanides and Glitazones
Antihypertensive Drugs: Thiazide-Class Diuretics
Dipeptidyl Peptidase 4 Inhibitors
Oral Hypoglycemic Agents: Sulfonylureas
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...